PureTech Health PLC PDMR Notification RSU Vesting (3711T)
July 22 2022 - 1:00PM
UK Regulatory
TIDMPRTC
RNS Number : 3711T
PureTech Health PLC
22 July 2022
22 July 2022
PureTech Health plc
PDMR Notifications
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company dedicated to
discovering, developing and commercializing highly differentiated
medicines for devastating diseases, announces that awards of
restricted share units ("RSUs") granted by PureTech on 21 July 2021
to certain non-executive directors ("PDMRs") pursuant to its
Performance Share Plan ("PSP") vested in full on 15 June 2022
immediately prior to the Company's Annual General Meeting of
Stockholders . Each PDMR received vested ordinary shares on 22 July
2022.
The Company's total issued ordinary share capital is 288,689,450
shares after the share issuance to the PDMRs, 3,563,665 shares of
which are held in treasury by the Company.
PDMR Notification
The information contained in the below notification is disclosed
in accordance with Article 19 of the EU Market Abuse
Regulation.
Details of the person discharging managerial responsibilities/person
1 closely associated
a) Name Raju Kucherlapati
John LaMattina
Robert Langer
Kiran Mazumdar-Shaw
Marjorie Scardino
Christopher Viehbacher
--------------------------------- -----------------------------------------------------
Reason for the notification
2
----------------------------------------------------------------------------------------
a) Position/status Non-Executive Directors
--------------------------------- -----------------------------------------------------
b) Initial notification/Amendment Initial Notification
--------------------------------- -----------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------------------
a) Name PureTech Health plc
--------------------------------- -----------------------------------------------------
b) LEI 213800LVPDNO2Z9T9I39
--------------------------------- -----------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----------------------------------------------------------------------------------------
a) Description Ordinary Shares of PureTech Health
of the financial plc
instrument, ISIN GB00BY2Z0H74
type of instrument
--------------------------------- -----------------------------------------------------
b) Nature of the Issuance of ordinary shares in settlement of
transaction certain vested RSUs under the PureTech Health
Performance Share Plan.
--------------------------------- -----------------------------------------------------
c) Price(s) and Recipient Price Amount
volume(s) Raju Kucherlapati 0.01 GBP 11,190 ordinary
shares
-------- ----------------
John LaMattina 0.01 GBP 11,190 ordinary
shares
-------- ----------------
Robert Langer 0.01 GBP 11,190 ordinary
shares
-------- ----------------
Kiran Mazumdar-Shaw 0.01 GBP 11,190 ordinary
shares
-------- ----------------
Marjorie Scardino 0.01 GBP 11,190 ordinary
shares
-------- ----------------
Christopher Viehbacher 0.01 GBP 11,190 ordinary
shares
-------- ----------------
--------------------------------- -----------------------------------------------------
d) Aggregated Price Aggregate Volume
information- Aggregated volume 0.01 GBP 67,140 ordinary shares
-----------------------
- Price
--------------------------------- -----------------------------------------------------
e) Date of the 22 July 2022
transaction
--------------------------------- -----------------------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--------------------------------- -----------------------------------------------------
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercializing highly
differentiated medicines for devastating diseases, including
inflammatory, fibrotic and immunological conditions, intractable
cancers, lymphatic and gastrointestinal diseases and neurological
and neuropsychological disorders, among others. The Company has
created a broad and deep pipeline through the expertise of its
experienced research and development team and its extensive network
of scientists, clinicians and industry leaders. This pipeline,
which is being advanced both internally and through PureTech's
Founded Entities, is comprised of 27 therapeutics and therapeutic
candidates, including two that have received both U.S. FDA
clearance and European marketing authorization, as of the date of
PureTech's most recently filed Annual Report and corresponding Form
6-K. All of the underlying programs and platforms that resulted in
this pipeline of therapeutic candidates were initially identified
or discovered and then advanced by the PureTech team through key
validation points based on unique insights in immunology and drug
development.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Contact:
PureTech
Investor Relations
IR@puretechhealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHPPUMPMUPPGBG
(END) Dow Jones Newswires
July 22, 2022 13:00 ET (17:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024
